GSK plans USD 800 million rebuild. GSK stock falls 1.04 percent

Published on 10/16/2026 at 10:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GSK's 2026 outlook keeps turnover growth at 3.00 to 5.00 percent. GSK stock costs EUR 21.90 on October 16, 2026, 1.04 percent below the Xetra close.

Pipeline spending meets earnings watch

On October 14, MarketBeat reported GSK's planned USD 800 million Pennsylvania rebuild.
For the second quarter of 2026, GSK turnover reached GBP 8.41 billion, up 5.00 percent.
GSK stock trades at EUR 21.90 at 10:10 a.m. CEST at Lang & Schwarz on October 16, 2026, 1.04 percent below the Xetra close of October 15, 2026.

Moderne Pharma-Produktionsanlage mit Glasfassade und Laboren bei Dämmerlicht — GSK plc (ISIN GB0009252882) betreibt moderne Pharmaanlagen mit Laboren und Produktionshallen in der Abenddämmerung, Illustration mit AI erstellt.

GSK (ISIN GB00BN7SWP63) was trading at EUR 21.90 at Lang & Schwarz on October 16, 2026 at 10:10 a.m. CEST, down 1.04 percent versus the Xetra close of October 15, 2026 at EUR 22.13. On October 14, MarketBeat reported that GSK planned to invest USD 800 million to rebuild its Pennsylvania manufacturing facility.

Pennsylvania spending widens the pipeline

The Upper Merion project is designed to strengthen United States manufacturing capacity, while GSK and Oxford University have begun dosing the first patient in an early-stage ulcerative colitis trial, according to MarketBeat. The trial expands the immunology pipeline, but its financial contribution belongs to the longer term.

Three recent milestones set the timeline

On October 8, GSK reaffirmed 2026 turnover growth of 3.00 to 5.00 percent and core operating profit growth of 7.00 to 9.00 percent in its GSK guidance update. On October 13, Proactive Investors reported that RBC retained a GBp 1,975.00 target and Sector Perform rating. On October 14, MarketBeat reported the USD 800 million Pennsylvania plan.

What will October bring for earnings?

RBC forecasts third-quarter revenue of GBP 8.82 billion versus GBP 8.89 billion consensus, while core earnings per share of GBp 50.80 are expected to match consensus, according to Proactive Investors. The same report identifies weaker vaccine demand as a counterweight to HIV and Nucala sales. GSK's next quarterly results are scheduled for October 28, 2026.

Upcoming dates carry clinical risk

The next two dated catalysts are a United States regulatory decision on bepirovirsen on October 26, 2026, and an oncology investor update on October 27, 2026, according to Proactive Investors. Together with the October 28 results, these dates put pipeline execution beside vaccine demand in the short-term investment narrative.

Stock sits below the Xetra close

On the London Stock Exchange, GSK was last at GBp 1,846.00 on October 16, 2026 at 9:18 a.m. BST, within its GBp 1,592.00 to GBp 2,282.00 52-week range. The euro quotation was trading at EUR 21.90 at Lang & Schwarz on October 16, 2026 at 10:10 a.m. CEST, 1.04 percent below the Xetra close of October 15, 2026 at EUR 22.13. The further course of trading is shown by the continuously updated real-time quote of GSK stock.